doxazosin has been researched along with Heart Failure in 40 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to evaluate the effect of carvedilol on nitrate tolerance in patients with chronic heart failure." | 9.08 | Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. ( Kakihana, M; Ohtsuka, S; Sugishita, Y; Watanabe, H, 1998) |
| "In this study we evaluated the effects of once-daily administration of oral doxazosin in patients with chronic congestive heart failure (CHF)." | 9.07 | Doxazosin for the treatment of chronic congestive heart failure: results of a randomized double-blind and placebo-controlled study. ( Chakko, S; DiBianco, R; Emmanuel, G; Marlon, A; Parker, JO; Singh, JB; Tanser, PH, 1991) |
| "Doxazosin treatment has been discouraged in hypertensive patients in order to prevent heart failure (HF) development." | 7.75 | Safety and efficacy of doxazosin as an "add-on" antihypertensive therapy in mild to moderate heart failure patients. ( Arioli, F; Cuko, A; Fragasso, G; Gardini, C; Margonato, A; Palloshi, A; Roccaforte, R; Salerno, A; Spoladore, R, 2009) |
| "Lower heart failure (HF) rates in individuals taking chlorthalidone vs amlodipine, lisinopril, or doxazosin were unanticipated in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)." | 5.14 | Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome? ( Barzilay, J; Cutler, JA; Dart, RA; Davis, BR; Graumlich, JF; Grimm, RH; Margolis, KL; Murden, RA; Piller, LB; Randall, OS, 2009) |
| " The double-blind, active-controlled component of ALLHAT was designed to determine whether the rate of the primary outcome-a composite of fatal coronary heart disease and nonfatal myocardial infarction-differs between diuretic (chlorthalidone) treatment and each of three other classes of antihypertensive drugs: a calcium antagonist (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), and an alpha-adrenergic blocker (doxazosin) in high-risk hypertensive persons ages 55 years and older." | 5.09 | Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Bettencourt, J; Davis, BR; Ford, CE; Furberg, CD; Geraci, TS; Kimmel, B; Kingry, C; Lusk, C; Nwachuku, C; Parks, H; Piller, LB; Pressel, SL; Simpson, LM; Wright, JT, 2001) |
| "This study was designed to evaluate the effect of carvedilol on nitrate tolerance in patients with chronic heart failure." | 5.08 | Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. ( Kakihana, M; Ohtsuka, S; Sugishita, Y; Watanabe, H, 1998) |
| "In this study we evaluated the effects of once-daily administration of oral doxazosin in patients with chronic congestive heart failure (CHF)." | 5.07 | Doxazosin for the treatment of chronic congestive heart failure: results of a randomized double-blind and placebo-controlled study. ( Chakko, S; DiBianco, R; Emmanuel, G; Marlon, A; Parker, JO; Singh, JB; Tanser, PH, 1991) |
| "Doxazosin treatment has been discouraged in hypertensive patients in order to prevent heart failure (HF) development." | 3.75 | Safety and efficacy of doxazosin as an "add-on" antihypertensive therapy in mild to moderate heart failure patients. ( Arioli, F; Cuko, A; Fragasso, G; Gardini, C; Margonato, A; Palloshi, A; Roccaforte, R; Salerno, A; Spoladore, R, 2009) |
| "ALLHAT, a randomized, double-blind, active-controlled hypertension treatment trial in 42,418 patients, reported that a thiazide-type diuretic (chlorthalidone) was superior to a calcium channel blocker (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), and an alpha1-blocker (doxazosin) in preventing the new onset of heart failure (HF)." | 3.74 | The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. ( Black, HR; Cushman, WC; Davis, BR; Einhorn, PT; Levy, D; Massie, BM; Nwachuku, CE; Piller, LB; Simpson, LM, 2007) |
| " To assess whether these differential structural effects do translate into different effects on LV function and on heart failure mortality, Bd or sham Bd 8-week-old rats were randomized to vehicle treatment (Vh), chemical sympathectomy ([Sx] 6-hydroxydopamine, 150 mg/kg IP twice a week), beta-adrenoceptor blockade (propranolol [Pro], 40 mg/kg per day PO), or alpha-adrenoceptor blockade (doxazosin [Dox], 5 mg/kg per day PO)." | 3.73 | Survival benefits of different antiadrenergic interventions in pressure overload left ventricular hypertrophy/failure. ( Busca, G; Cesana, F; Clari, F; Ferrari, AU; Ferrero, I; Gatti, C; Janetti, MB; Mancia, G; Palladini, G; Perlini, S; Tozzi, R; Vezzoli, M, 2006) |
| "Background Hypertension is a known risk factor for heart failure ( HF ), possibly via the mechanism of cardiac remodeling and left ventricular hypertrophy ( LVH )." | 2.90 | Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study. ( Davis, BR; Johnson, K; Oparil, S; Tereshchenko, LG, 2019) |
| "Hypertension is a major cause of heart failure (HF) and is antecedent in 91% of cases." | 2.72 | Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ( Colon, P; Crow, R; Cutler, JA; Davis, BR; Dunn, K; Ellsworth, A; Franklin, S; Furberg, C; Goff, D; Golden, J; Leenen, F; Mohiuddin, S; Papademetriou, V; Piller, LB; Proschan, M, 2006) |
| "The doxazosin arm was terminated early, when the trial's safety and monitoring board noted a twofold higher incidence of congestive heart failure in patients receiving doxazosin than in those receiving chlorthalidone (8." | 1.31 | Alpha-blockers and congestive heart failure: early termination of an arm of the ALLHAT trial. ( Vidt, DG, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (7.50) | 18.2507 |
| 2000's | 34 (85.00) | 29.6817 |
| 2010's | 3 (7.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Drzayich Antol, D | 1 |
| Waldman Casebeer, A | 1 |
| Khoury, R | 1 |
| Michael, T | 1 |
| Renda, A | 1 |
| Hopson, S | 1 |
| Parikh, A | 1 |
| Stein, A | 1 |
| Costantino, M | 1 |
| Stemkowski, S | 1 |
| Bunce, M | 1 |
| Nevo, N | 1 |
| Abu-Abeid, S | 1 |
| Hazzan, D | 1 |
| Lahat, G | 1 |
| Nachmani, I | 1 |
| Eldar, SM | 1 |
| Zhang, L | 1 |
| Xia, X | 1 |
| Zhong, Y | 1 |
| Xie, D | 1 |
| Liu, S | 1 |
| Wang, X | 1 |
| Tu, J | 1 |
| Faconti, L | 1 |
| Mills, CE | 1 |
| Govoni, V | 1 |
| Gu, H | 1 |
| Morant, S | 1 |
| Jiang, B | 1 |
| Cruickshank, JK | 1 |
| Webb, AJ | 1 |
| Lin, J | 1 |
| Wu, YJ | 1 |
| Liang, X | 1 |
| Ji, M | 1 |
| Ying, HM | 1 |
| Wang, XY | 1 |
| Sun, X | 1 |
| Shao, CH | 1 |
| Zhan, LX | 1 |
| Zhang, Y | 1 |
| Czamara, K | 1 |
| Karnas, E | 1 |
| Majka, Z | 1 |
| Wojcik, T | 1 |
| Zuba-Surma, EK | 1 |
| Baranska, M | 1 |
| Kaczor, A | 1 |
| Liu, X | 1 |
| Zhou, F | 1 |
| Yang, Y | 1 |
| Wang, W | 1 |
| Niu, L | 1 |
| Zuo, D | 1 |
| Li, X | 1 |
| Hua, H | 1 |
| Zhang, B | 1 |
| Kou, Y | 1 |
| Guo, J | 1 |
| Kong, F | 1 |
| Pan, W | 1 |
| Gao, D | 1 |
| Meves, JM | 1 |
| Sun, H | 1 |
| Xue, M | 1 |
| Zhang, Q | 1 |
| Wang, Y | 1 |
| Tang, R | 1 |
| Iso, T | 1 |
| Haruyama, H | 1 |
| Sunaga, H | 1 |
| Matsui, H | 1 |
| Matsui, M | 1 |
| Tanaka, R | 1 |
| Umbarawan, Y | 1 |
| Syamsunarno, MRAA | 1 |
| Putri, M | 1 |
| Yamaguchi, A | 1 |
| Hanaoka, H | 1 |
| Negishi, K | 1 |
| Yokoyama, T | 1 |
| Kurabayashi, M | 1 |
| Palomo-Briones, R | 1 |
| Esquivel-González, S | 1 |
| Aizpuru, A | 1 |
| Gómez-Hernández, N | 1 |
| Casas-Flores, S | 1 |
| Barba de la Rosa, AP | 1 |
| Arriaga, S | 1 |
| Peterson, ME | 1 |
| Carothers, MA | 1 |
| Gamble, DA | 1 |
| Rishniw, M | 1 |
| Johnson, K | 1 |
| Oparil, S | 1 |
| Davis, BR | 6 |
| Tereshchenko, LG | 1 |
| Kostis, JB | 1 |
| Simpson, LM | 3 |
| Black, HR | 2 |
| Cushman, WC | 2 |
| Einhorn, PT | 2 |
| Farber, MA | 1 |
| Ford, CE | 2 |
| Levy, D | 2 |
| Massie, BM | 2 |
| Nawaz, S | 1 |
| Barrios, V | 1 |
| Escobar, C | 1 |
| Tomás, JP | 1 |
| Calderon, A | 1 |
| Echarri, R | 1 |
| Spoladore, R | 1 |
| Roccaforte, R | 1 |
| Fragasso, G | 1 |
| Gardini, C | 1 |
| Palloshi, A | 1 |
| Cuko, A | 1 |
| Arioli, F | 1 |
| Salerno, A | 1 |
| Margonato, A | 1 |
| Grimm, RH | 1 |
| Piller, LB | 4 |
| Cutler, JA | 2 |
| Margolis, KL | 1 |
| Barzilay, J | 1 |
| Dart, RA | 1 |
| Graumlich, JF | 1 |
| Murden, RA | 1 |
| Randall, OS | 1 |
| Chapman, N | 1 |
| Chen, CY | 1 |
| Fujita, T | 1 |
| Hobbs, FD | 1 |
| Kim, SJ | 1 |
| Staessen, JA | 1 |
| Tanomsup, S | 1 |
| Wang, JG | 1 |
| Williams, B | 1 |
| Paran, E | 1 |
| Düsing, R | 1 |
| Lohm, L | 1 |
| Lindh, E | 1 |
| Frösing, R | 1 |
| Järhult, B | 2 |
| Lindahl, SO | 2 |
| Furberg, C | 2 |
| Gustafsson, LL | 1 |
| Cervera Casino, P | 1 |
| Ruiz García, V | 1 |
| Gervas Camacho, J | 1 |
| Kieback, AG | 1 |
| Rödiger, O | 1 |
| Jaenecke, H | 1 |
| Grohmann, A | 1 |
| Wernecke, KD | 1 |
| Baumann, G | 1 |
| Felix, SB | 1 |
| Dunn, K | 1 |
| Franklin, S | 1 |
| Goff, D | 1 |
| Leenen, F | 1 |
| Mohiuddin, S | 1 |
| Papademetriou, V | 1 |
| Proschan, M | 1 |
| Ellsworth, A | 1 |
| Golden, J | 1 |
| Colon, P | 1 |
| Crow, R | 1 |
| Yusuf, S | 1 |
| Perlini, S | 1 |
| Ferrero, I | 1 |
| Palladini, G | 1 |
| Tozzi, R | 1 |
| Gatti, C | 1 |
| Vezzoli, M | 1 |
| Cesana, F | 1 |
| Janetti, MB | 1 |
| Clari, F | 1 |
| Busca, G | 1 |
| Mancia, G | 1 |
| Ferrari, AU | 1 |
| Nwachuku, CE | 1 |
| Kukin, ML | 1 |
| Kalman, J | 1 |
| Mannino, M | 1 |
| Freudenberger, R | 1 |
| Buchholz, C | 1 |
| Ocampo, O | 1 |
| Watanabe, H | 1 |
| Kakihana, M | 1 |
| Ohtsuka, S | 1 |
| Sugishita, Y | 1 |
| SoRelle, R | 1 |
| Messerli, FH | 3 |
| Ball, SG | 1 |
| Thackray, S | 1 |
| Witte, K | 1 |
| Clark, AL | 1 |
| Cleland, JG | 1 |
| Vidt, DG | 1 |
| Grossman, E | 1 |
| Hansson, L | 1 |
| Feldman, RD | 1 |
| Campbell, N | 1 |
| Larochelle, P | 1 |
| Osnes, JB | 1 |
| Aass, H | 1 |
| Andersen, GO | 1 |
| Skomedal, T | 1 |
| Pressel, SL | 1 |
| Wright, JT | 1 |
| Geraci, TS | 1 |
| Kingry, C | 1 |
| Bettencourt, J | 1 |
| Kimmel, B | 1 |
| Lusk, C | 1 |
| Parks, H | 1 |
| Nwachuku, C | 1 |
| Furberg, CD | 1 |
| McLellan, F | 1 |
| Faulhaber, HD | 1 |
| Simon, HB | 1 |
| Kjeldsen, SE | 1 |
| DiBianco, R | 1 |
| Parker, JO | 1 |
| Chakko, S | 1 |
| Tanser, PH | 1 |
| Emmanuel, G | 1 |
| Singh, JB | 1 |
| Marlon, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268] | Phase 4 | 107 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for doxazosin and Heart Failure
| Article | Year |
|---|---|
Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension?
Topics: Adrenergic alpha-1 Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Clinical Trials as | 2010 |
Doxazosin and congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Adverse Drug Reaction Reporting Systems; Angiotensin-Converting Enzyme | 2001 |
13 trials available for doxazosin and Heart Failure
| Article | Year |
|---|---|
Topics: Adult; Aged; Animals; Astrocytes; Bariatric Surgery; Beta vulgaris; Bioreactors; Biotechnology; Bloo | 2018 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Antihypertensive Agents; Coronary Disease; Double-Bl | 2008 |
Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome?
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Confidence Intervals; Double-Blind Meth | 2009 |
Hemodynamic effects of alpha1-adrenoceptor antagonist, doxazosin, in patients with chronic congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Aged; Chronic Disease; Double-Blind Method; Doxazosin; Electrocardiogr | 2005 |
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2006 |
Combined alpha-beta blockade (doxazosin plus metoprolol) compared with beta blockade alone in chronic congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Chronic Disease; Doxazosin; | 1996 |
Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure.
Topics: Adrenergic Antagonists; Aged; Blood Flow Velocity; Blood Platelets; Blood Pressure; Carbazoles; Carv | 1998 |
National Heart, Lung, and Blood Institute halts part of antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
Topics: Adrenergic alpha-Antagonists; Anticholesteremic Agents; Chlorthalidone; Diuretics; Doxazosin; Female | 2000 |
Implications of discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adverse Drug Reaction Reporting Systems; Anticholesteremic Agents; Antihypertensive Agents; Chlortha | 2000 |
Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme | 2000 |
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adverse Drug Reaction Reporting Systems; Antihypertensive Agents; Cause of Death; Coronary Disease; | 2001 |
Doxazosin for the treatment of chronic congestive heart failure: results of a randomized double-blind and placebo-controlled study.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Doxazosin; Exercise; Female; Heart Failure; Hemod | 1991 |
25 other studies available for doxazosin and Heart Failure
| Article | Year |
|---|---|
Doxazosin and heart failure: to be or not to be.
Topics: Antihypertensive Agents; Doxazosin; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricul | 2009 |
Safety and efficacy of doxazosin as an "add-on" antihypertensive therapy in mild to moderate heart failure patients.
Topics: Aged; Antihypertensive Agents; Doxazosin; Female; Heart Failure; Hospitalization; Humans; Hypertensi | 2009 |
Doxazosin and ALLHAT trial: a response.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Doxazos | 2002 |
[The new (old) knowledge in primary prevention of stroke. It depends on lowering of blood pressure].
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2003 |
[Alfadil and heart failure--clinical conclusions do exist!].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Doxazosin; Drug Information Services; Heart Failu | 2003 |
[Doxazosin and heart failure: truthful information--for the sake of patients].
Topics: Antihypertensive Agents; Doxazosin; Drug Information Services; Heart Failure; Humans | 2003 |
[Doxazosin and heart failure: a clinical conclusion is wanted].
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Doxazosin; Heart Failure; Humans; Hypertensio | 2003 |
[Alfadil--positive documentation when it comes to safety is missing].
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Documentation; Doxazosin; Drug Information Se | 2003 |
[Choice of antihypertensive agent--insignificant role of doxazosin (Alfadil). How are evidence-based recommendations implemented?].
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Contraindications; Doxazosin; Evidence-Based | 2004 |
[Antihypertensive therapy and congestive heart failure].
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Doxazosin; Drug Utilization; Heart Failure; H | 2005 |
Preventing vascular events due to elevated blood pressure.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Comorbidity; Doxazosin; Drug Thera | 2006 |
Survival benefits of different antiadrenergic interventions in pressure overload left ventricular hypertrophy/failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Aorta, Abdominal; Blood Pressure | 2006 |
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2007 |
Discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack.
Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Heart Failure; Humans | 2000 |
Diuretics vs. alpha blockers.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Ca | 2000 |
Alpha-blockers and congestive heart failure: early termination of an arm of the ALLHAT trial.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Chlorthalidone; Doxazosin; Female; Heart Fail | 2000 |
Doxazosin arm of the ALLHAT study discontinued: how equal are antihypertensive drugs? Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2000 |
First-line antihypertensive therapy.
Topics: Antihypertensive Agents; Doxazosin; Heart Failure; Humans; Myocardial Infarction; Randomized Control | 2000 |
First-line antihypertensive therapy. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Doxazosin; Heart Failure; Humans; Randomized | 2000 |
First-line antihypertensive therapy.
Topics: Antihypertensive Agents; Chlorthalidone; Doxazosin; Heart Failure; Humans; Myocardium; Randomized Co | 2000 |
US FDA weighs options for warning on antihypertensive drug.
Topics: Antihypertensive Agents; Doxazosin; Drug Labeling; Heart Failure; Humans; United States; United Stat | 2001 |
[Alpha-blockers in therapy of arterial hypertension. No longer the drug of first choice].
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Cause of Death; Chlorthalidone; Doxazos | 2001 |
On call. I'm a 76-year-old man with an enlarged prostate. I've been taking Cardura and it's helped a lot, but my doctor stopped it because he said a study found the drug could cause heart failure. Now I'm getting up three or four times a night again. Is C
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Doxazosin; Heart Failure; Humans; Hyper | 2001 |
Heart lines. Cardura update.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Diuretics; Doxazosin; Heart Failure; Humans; | 2001 |
Warning for antihypertensive drug?
Topics: Antihypertensive Agents; Clinical Trials as Topic; Doxazosin; Drug Labeling; Heart Failure; Humans; | 2001 |